NCT06755840 Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study
| NCT ID | NCT06755840 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiangya Hospital of Central South University |
| Condition | Sleep Disordered Breathing (SDB) |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2025-01-15 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2025-01-15 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sleep disordered breathing (SDB) is one of the most common sleep disorders, including obstructive sleep apnea (OSA), central sleep apnea (CSA), sleep-related hypoventilation, hypoxemia, etc., with OSA being the most prevalent. Also, SDB shows high comorbidities with multisystem diseases. Furthermore, compared to patients with pure SDB, those comorbid with SDB and other disorders like cardiometabolic dysfunction and cognitive impairment experience poorer quality of life, higher rate of disease progression and mortality, and a greater economic burden. Currently, there are limited cohorts to study the associations between SDB and multisystem diseases. The aim of this study is to establish an ambispective clinical cohort for SDB in Xiangya hospital from central-south China (Xiangya Sleep Disordered Breathing Cohort, Xiangya SDB cohort) including retrospective part and prospective part, which covers multi-dimensional data of sleep monitoring, demographic, daily behaviors, clinical manifestations and comorbidities status, life quality, treatment information and evaluation, etc. by self-reported questionnaires and objective assessments and tests. Besides, whole peripheral blood is drawn for following biomarkers study and omics analysis. The main goal is to achieve precise management of SDB and related multimorbidity, containing to early identify risk individuals for multisystem impairment, significantly improve their prognosis and ultimately enhance overall health. In detail: first, to reveal how multisystem impairment related to SDB evolves; second, to identify which indicators closely involve system dysfunction due to SDB; third, to build an efficient model and a cost-effective platform to screen high-risk population and tract therapeutic effect.
Eligibility Criteria
Inclusion Criteria: * 1\) Participants who were suspected of sleep disordered breathing must complete at least one overnight sleep monitoring at the Sleep Medicine Center at Xiangya Hospital. * 2\) Participants can finish any assessment for each comorbid system by questionnaires, scales, physical examinations and tests, etc. independently or with the assistance. * 3\) Participants agreed to participate in this study with signing an informed consent form. Exclusion Criteria: * Participants who refused to participate in this study or whose clinical data was lost.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06755840 clinical trial?
This trial is open to participants of all sexes, studying Sleep Disordered Breathing (SDB). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06755840 currently recruiting?
Yes, NCT06755840 is actively recruiting participants. Contact the research team at zhangyuan9194@csu.edu.cn for enrollment information.
Where is the NCT06755840 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT06755840 clinical trial?
NCT06755840 is sponsored by Xiangya Hospital of Central South University. The trial plans to enroll 15,000 participants.